GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Arzneiwerk AG VIDA (LTS:0NKY) » Definitions » EV-to-EBIT

Arzneiwerk AG VIDA (LTS:0NKY) EV-to-EBIT : -11.51 (As of Oct. 31, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Arzneiwerk AG VIDA EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Arzneiwerk AG VIDA's Enterprise Value is €16.32 Mil. Arzneiwerk AG VIDA's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.42 Mil. Therefore, Arzneiwerk AG VIDA's EV-to-EBIT for today is -11.51.

The historical rank and industry rank for Arzneiwerk AG VIDA's EV-to-EBIT or its related term are showing as below:

LTS:0NKY' s EV-to-EBIT Range Over the Past 10 Years
Min: -340.63   Med: 1.03   Max: 53.49
Current: -11.52

During the past 13 years, the highest EV-to-EBIT of Arzneiwerk AG VIDA was 53.49. The lowest was -340.63. And the median was 1.03.

LTS:0NKY's EV-to-EBIT is ranked worse than
100% of 84 companies
in the Medical Distribution industry
Industry Median: 13.01 vs LTS:0NKY: -11.52

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Arzneiwerk AG VIDA's Enterprise Value for the quarter that ended in Jun. 2024 was €21.02 Mil. Arzneiwerk AG VIDA's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.42 Mil. Arzneiwerk AG VIDA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -6.74%.


Arzneiwerk AG VIDA EV-to-EBIT Historical Data

The historical data trend for Arzneiwerk AG VIDA's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arzneiwerk AG VIDA EV-to-EBIT Chart

Arzneiwerk AG VIDA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 5.12 -162.57 -12.57 -4.62

Arzneiwerk AG VIDA Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.25 -5.82 -4.62 -12.45 -12.04

Competitive Comparison of Arzneiwerk AG VIDA's EV-to-EBIT

For the Medical Distribution subindustry, Arzneiwerk AG VIDA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arzneiwerk AG VIDA's EV-to-EBIT Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Arzneiwerk AG VIDA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Arzneiwerk AG VIDA's EV-to-EBIT falls into.



Arzneiwerk AG VIDA EV-to-EBIT Calculation

Arzneiwerk AG VIDA's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=16.316/-1.417
=-11.51

Arzneiwerk AG VIDA's current Enterprise Value is €16.32 Mil.
Arzneiwerk AG VIDA's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arzneiwerk AG VIDA  (LTS:0NKY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Arzneiwerk AG VIDA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-1.417/21.022472
=-6.74 %

Arzneiwerk AG VIDA's Enterprise Value for the quarter that ended in Jun. 2024 was €21.02 Mil.
Arzneiwerk AG VIDA's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arzneiwerk AG VIDA EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Arzneiwerk AG VIDA's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Arzneiwerk AG VIDA Business Description

Traded in Other Exchanges
Address
Ordensmeisterstrasse 15-16, Berlin, DEU, 12099
Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe which usually includes high-priced drugs for chronic, complex, or rare diseases such as oncology, neurology, autoimmune diseases, ophthalmology, hemophilia, and infectious diseases.

Arzneiwerk AG VIDA Headlines

No Headlines